Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)

NCT02632045 is registered in ClinicalTrials.gov with Melissa K Accordino as lead sponsor.

NCT NCT02632045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02632045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Lead sponsor
Melissa K Accordino
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
January 4, 2022
Enrollment
169 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, metastatic breast cancer